{
    "nct_id": "NCT04745689",
    "official_title": "A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer",
    "inclusion_criteria": "* Documented evidence of extensive stage SCLC (ES-SCLC)\n* Participants must be considered suitable to receive an induction platinum-based chemotherapy regimen, combined with durvalumab, as first-line treatment for ES-SCLC\n* No prior exposure to immune-mediated therapy\n* Life expectancy â‰¥12 weeks at Day 1.\n* ECOG 0 or 1 at enrolment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy\n* Has a paraneoplastic syndrome (PNS) of autoimmune nature, requiring systemic treatment (systemic steroids or immunosuppressive agents) or has a clinical symptomatology suggesting worsening of PNS\n* Active infection including tuberculosis, HIV, hepatitis B and C\n* Active or prior documented autoimmune or inflammatory disorders\n* Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.",
    "miscellaneous_criteria": ""
}